These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 9791317)

  • 1. Zenapax: transplant's first humanized monoclonal antibody.
    Bell J; Colaneri J
    ANNA J; 1998 Aug; 25(4):429-30. PubMed ID: 9791317
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of daclizumab (zenapax) on prevention of acute rejection of renal transplantation.
    Poorrezagholi F; Einollahi B; Firoozan A; Nafar M; Yadegari H; Moghaddam SM; Simforoosh N; Basiri A; Farhangi S
    Transplant Proc; 2003 Nov; 35(7):2735-6. PubMed ID: 14612098
    [No Abstract]   [Full Text] [Related]  

  • 3. Zenapax (daclizumab) reduces the incidence of acute rejection episodes and improves patient survival following renal transplantation. No 14874 and No 14393 Zenapax Study Groups.
    Ekberg H; Bäckman L; Tufveson G; Tydén G
    Transplant Proc; 1999; 31(1-2):267-8. PubMed ID: 10083102
    [No Abstract]   [Full Text] [Related]  

  • 4. The interleukin-2 inhibitors and their role in low-toxicity regimens.
    Nashan B
    Transplant Proc; 1999 Dec; 31(8A):23S-26S. PubMed ID: 10616557
    [No Abstract]   [Full Text] [Related]  

  • 5. New monoclonal antibodies to prevent transplant rejection.
    Med Lett Drugs Ther; 1998 Sep; 40(1036):93-4. PubMed ID: 9774964
    [No Abstract]   [Full Text] [Related]  

  • 6. Daclizumab to prevent acute rejection in renal transplantation.
    Abramowicz D
    N Engl J Med; 1998 Jun; 338(23):1700-1. PubMed ID: 9616069
    [No Abstract]   [Full Text] [Related]  

  • 7. B-cell-depleting induction therapy and acute cellular rejection.
    Clatworthy MR; Watson CJ; Plotnek G; Bardsley V; Chaudhry AN; Bradley JA; Smith KG
    N Engl J Med; 2009 Jun; 360(25):2683-5. PubMed ID: 19535812
    [No Abstract]   [Full Text] [Related]  

  • 8. Daclizumab: outcome of phase III trials and mechanism of action. Double Therapy and the Triple Therapy Study Groups.
    Vincenti F; Nashan B; Light S
    Transplant Proc; 1998 Aug; 30(5):2155-8. PubMed ID: 9723424
    [No Abstract]   [Full Text] [Related]  

  • 9. Monoclonal antibody approved for renal transplants.
    Am J Health Syst Pharm; 1998 Feb; 55(3):207-8. PubMed ID: 9492247
    [No Abstract]   [Full Text] [Related]  

  • 10. Review and preview of anti-T-cell antibodies.
    Helderman JH
    Transplant Proc; 1995 Oct; 27(5 Suppl 1):8-9. PubMed ID: 7482824
    [No Abstract]   [Full Text] [Related]  

  • 11. New therapeutic monoclonal antibodies target kidney transplant rejection and cancer.
    Piascik P
    J Am Pharm Assoc (Wash); 1998; 38(3):379-80. PubMed ID: 9654869
    [No Abstract]   [Full Text] [Related]  

  • 12. Immunosuppressive drugs for kidney transplantation.
    Halloran PF
    N Engl J Med; 2004 Dec; 351(26):2715-29. PubMed ID: 15616206
    [No Abstract]   [Full Text] [Related]  

  • 13. Anti-IL-2 receptor antibodies versus anti-thymocyte globulin for induction therapy in kidney transplantation.
    Mandelbrot D
    J Am Soc Nephrol; 2009 Jun; 20(6):1170-1. PubMed ID: 19470672
    [No Abstract]   [Full Text] [Related]  

  • 14. Prophylactic use of the anti-IL-2 receptor monoclonal antibody LO-Tact-1 in cadaveric renal transplantation: results of a randomized study.
    Kriaa F; Hiesse C; Alard P; Lantz O; Noury J; Charpentier B; Bazin H
    Transplant Proc; 1993 Feb; 25(1 Pt 1):817-9. PubMed ID: 8438496
    [No Abstract]   [Full Text] [Related]  

  • 15. Daclizumab rapidly saturates interleukin-2 receptor-alpha (CD25) on lymph node lymphocytes in children.
    Savo AM; Book BK; Henson S; Hakimi J; Pescovitz MD
    Transplant Proc; 1999; 31(1-2):1182-3. PubMed ID: 10083528
    [No Abstract]   [Full Text] [Related]  

  • 16. CD4 monoclonal antibodies in the preclinical dog renal allograft model.
    Watson CJ; Davies HS; Metcalfe SM; Cobbold SP; Rebello PR; Collier DS; Waldmann H; Calne RY
    Transplant Proc; 1993 Feb; 25(1 Pt 1):804-6. PubMed ID: 8438491
    [No Abstract]   [Full Text] [Related]  

  • 17. Is there any role for antithymocyte induction in renal transplantation?
    Neidlinger NA; Sollinger HW
    Transplant Proc; 2010 Jun; 42(5):1402-7. PubMed ID: 20620444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Campath-1H immunosuppressive therapy reduces incidence and intensity of acute rejection in intestinal and multivisceral transplantation.
    Garcia M; Weppler D; Mittal N; Nishida S; Kato T; Tzakis A; Ruiz P
    Transplant Proc; 2004 Mar; 36(2):323-4. PubMed ID: 15050146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunosuppression in cardiac transplantation.
    Hosenpud JD
    N Engl J Med; 2005 Jun; 352(26):2749-50. PubMed ID: 15987926
    [No Abstract]   [Full Text] [Related]  

  • 20. [Long-term therapeutic effect of Zenapax after renal transplantation].
    Liu W; Ling JY
    Zhonghua Yi Xue Za Zhi; 2009 Sep; 89(36):2565-7. PubMed ID: 20137620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.